# Transcranial Direct Current Stimulation Plus Monoclonal Antibodies Acting on the CGRP Pathway for Migraine

> **NCT05161871** · NA · COMPLETED · sponsor: **University of L'Aquila** · enrollment: 30 (actual)

## Conditions studied

- Migraine

## Interventions

- **DEVICE:** Cathodal transcranial direct current stimulation
- **DEVICE:** Sham cathodal transcranial direct current stimulation

## Key facts

- **NCT ID:** NCT05161871
- **Lead sponsor:** University of L'Aquila
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2023-01-16
- **Final completion:** 2023-04-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161871, "Transcranial Direct Current Stimulation Plus Monoclonal Antibodies Acting on the CGRP Pathway for Migraine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05161871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*